Method for making a solid-supported phospholipid bilayer
10787470 ยท 2020-09-29
Assignee
Inventors
Cpc classification
B32B9/04
PERFORMING OPERATIONS; TRANSPORTING
B05D7/24
PERFORMING OPERATIONS; TRANSPORTING
B05D2203/30
PERFORMING OPERATIONS; TRANSPORTING
B82Y40/00
PERFORMING OPERATIONS; TRANSPORTING
International classification
B05D7/24
PERFORMING OPERATIONS; TRANSPORTING
B82Y40/00
PERFORMING OPERATIONS; TRANSPORTING
B05D3/00
PERFORMING OPERATIONS; TRANSPORTING
Abstract
A method of preparing a solid-supported phospholipid bilayer is provided. The method includes a) a first step of providing a solution comprising a bicellar mixture of a long-chain phospholipid and a short-chain phospholipid; b) at least one second step of decreasing the temperature of the solution to below 0 C., increasing the temperature to above room temperature and causing the solution to be blended; and c) a third step of depositing the solution obtained after the second step on a surface of a support, wherein the concentration of the long-chain phospholipid in the solution is at most 0.1 mg/mL, for obtaining a solid-supported phospholipid bilayer. A solid-supported phospholipid layer obtained by the method as defined above is also provided.
Claims
1. A method of preparing a solid-supported phospholipid bilayer, the method comprising: a) a first step of providing a solution comprising a bicellar mixture of a long-chain phospholipid and a short-chain phospholipid; b) at least one second step of decreasing the temperature of the solution to below 0 C., increasing the temperature to above room temperature and causing the solution to be blended; and c) a third step of depositing the solution obtained after the second step on a surface of a support, wherein a concentration of the long-chain phospholipid in the solution is at most 0.1 mg/mL, for obtaining a solid-supported phospholipid bilayer.
2. The method of claim 1, wherein the long-chain phospholipid is a phospholipid comprising two fatty acid residues, wherein each of the fatty acid residues has more than 10 carbons.
3. The method of claim 1, wherein at least one of the long-chain phospholipid and the short-chain phospholipid is a phosphatidylcholine.
4. The method of claim 1, wherein the long-chain phospholipid has a gel-to-fluid-phase transition temperature of below 0 C.
5. The method of claim 1, wherein the short-chain phospholipid is a phospholipid comprising two fatty acid residues, wherein each of the fatty acid residues has at most 10 carbons.
6. The method of claim 1, wherein at least one of the long-chain phospholipid and the short-chain phospholipid comprises an unsaturated fatty acid residue.
7. The method of claim 1, wherein the short-chain phospholipid is 1,2-dihexyanoyl-sn-glycero-3-phosphocholine and the long-chain phospholipid is 1,2-dioleoyl-sn-glycero-3-phosphocholine.
8. The method of claim 1, wherein the concentration of the long-chain phospholipid in the solution of the third step is below 0.05 mg/mL.
9. The method of claim 1, wherein the long-chain phospholipid and the short-chain phospholipid are provided in a molar ratio of about 1:0.02 to about 1:5.
10. The method of claim 1, wherein the solution of the second step after blending is diluted in order to obtain the concentration of the long-chain phospholipid in the solution being at most 0.1 mg/mL.
11. The method of claim 1, wherein the solvent used to make the solution is a water-based buffer solution.
12. The method of claim 1, wherein the support is an inorganic material.
13. The method of claim 1, wherein the surface of the support is substantially planar.
14. The method of claim 1, wherein the surface of the support is nanostructured.
15. The method of claim 1, wherein in the third step, the bicellar mixture ruptures in order to obtain the solid-supported phospholipid bilayer.
16. The method of claim 1, wherein decreasing the temperature of the solution to below 0 C. in the at least one second step comprises decreasing the temperature of the solution to below 10 C.
17. The method of claim 1, wherein increasing the temperature to above room temperature in the at least one second step comprises increasing the temperature to above 30 C.
18. The method of claim 1, wherein the second step is repeated for about at least 2 times.
19. The method of claim 1, wherein the obtained solid-supported phospholipid bilayer is a planar phospholipid bilayer on the support.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1) The invention will be better understood with reference to the detailed description when considered in conjunction with the non-limiting examples and the accompanying drawings, in which:
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
DETAILED DESCRIPTION
(16) Various embodiments refer in a first aspect to a method of preparing a solid-supported phospholipid bilayer. The method comprises a) a first step of providing a solution comprising a bicellar mixture of a long-chain phospholipid and a short-chain phospholipid; b) at least one second step of decreasing the temperature of the solution to below 0 C., increasing the temperature to above room temperature and causing the solution to be blended; and c) a third step of depositing the solution obtained after the second step on a surface of a support, wherein the concentration of the long-chain phospholipid in the solution is at most 0.1 mg/mL, for obtaining a solid-supported phospholipid bilayer.
(17) The term phospholipid bilayer as used herein refers to a membrane which substantially consists of two layers, wherein each layer substantially consists of phospholipids. The layers are arranged in such a way, that they have a hydrophobic interior and a hydrophilic exterior. Each phospholipid molecule has a hydrophilic portion, which is in general the phosphorous-containing functional group, and a hydrophobic portion, which is an alkyl or alkylene chain resulting from a fatty acid. The hydrophobic interior therefore comprises the hydrophobic fatty acid alkyl/alkylene chains, whereas the hydrophilic exterior comprises the phosphorous-containing functional group. The hydrophilic portion, which is in general the phosphorous-containing functional group, may be any phosphate ester, which carries at least one negative charge in order to exhibit hydrophilicity. Illustratively, a phospholipid may be described by the Formula (I):
(18) ##STR00001## wherein each R.sub.1 and R.sub.2 individually represent a long chain saturated or unsaturated fatty acid moiety and R.sub.3 is selected from oxide (O.sup.) or a moiety OR.sub.4, wherein R.sub.4 may be selected from the group consisting of an optionally substituted C.sub.1-20 alkyl, an optionally substituted C.sub.1-20 cycloalkyl and an amino acid.
(19) The optionally substituted C.sub.1-20 alkyl may be selected from the group consisting of a C.sub.1-20 alkylalcohol or a C.sub.1-20 alkylamine.
(20) The C.sub.1-20 alkylalcohol may refer to a C.sub.1-20 alkyl chain which is substituted with 1 to 5 hydroxy moieties. When R.sub.4 is a C.sub.1-20 alkylalcohol, R.sub.3 may therefore be, for example, glycerol.
(21) The C.sub.1-20 alkylamine may refer to a C.sub.1-20 alkyl chain which is substituted with 1 to 5 amine moieties. The amine moieties may optionally be further alkylated, optionally with 1 to 3 alkyl moieties. Hence, the at least one amine moiety within R.sub.4 may be an ammonium cation. Advantageously, in embodiments wherein R.sub.4 comprises an ammonium moiety, R.sub.3 would comprise an additional charged moiety, which contributes to a higher hydrophilicity within the phosphorous-containing functional group. When R.sub.4 is a C.sub.1-20 alkylamine, wherein the C.sub.1-20 alkylamine comprises the amine as an ammonium moiety, R.sub.3 may therefore be, in one example, choline.
(22) When R.sub.4 is a C.sub.1-20 alkylamine, wherein the C.sub.1-20 alkylamine comprises an unsubstituted amine moiety, R.sub.3 may therefore be, for example, ethanolamine.
(23) The optionally substituted C.sub.1-20 cycloalkyl may refer to a C.sub.1-20 cycloalkyl which may be unsubstituted or substituted with 1 to 5 hydroxy moieties. When R.sub.4 is a hydroxylated C.sub.1-20 cycloalkyl, R.sub.3 may therefore be, for example, inositol.
(24) When R.sub.4 is an amino acid, the amino acid may be linked to the oxygen pendant on R.sub.3 with an oxygen derived from the side chain of the amino acid. This oxygen may be, for example, a hydroxyl moiety pendant on the side chain of the amino acid. Such amino acids may be, for example, serine, threonine or tyrosine. When R.sub.4 is an amino acid, R.sub.3 may therefore be, for example, serine.
(25) A long-chain phospholipid and a short-chain phospholipid may be used, in the first instance, as a relative term. It indicates that at least two types of phospholipids are used, wherein one phospholipid has a longer fatty acid moiety (R.sub.1 and R.sub.2 in Formula (I) above) than the other. The moieties R.sub.1 and R.sub.2 may be derived from unsaturated or saturated fatty acids. Hence, R.sub.1 and R.sub.2 may either comprise an alkyl chain or an alkylene chain. In the long-chain and the short-chain phospholipid, R.sub.1 and R.sub.2 may either be the same or different from each other. The long-chain phospholipid may be selected from a group comprising or consisting of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-myristoyl-sn-glycero-3-phosphocholine (PMPC), 1-stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine (SPPC) and 1,2-diarachidonoyl-sn-glycero-3-phosphocholine (DAPC), being preferably DOPC. In the same manner, the short-chain phospholipid used in the method may be selected from a group comprising or consisting of 1,2-dihexyanoyl-sn-glycero-3-phosphocholine (DHPC.sub.6), 1,2-dipentanoyl-sn-glycero-3-phosphocholine, 1,2-diheptanoyl-sn-glycero-3-phosphocholine (DHPC.sub.7), and 1,2-dioctanoyl-sn-glycero-3-phosphocholine, preferably being DHPC.sub.6.
(26) Advantageously, the critical micelle concentration (CMC) of the long-chain phospholipid may be different from the CMC of the short-chain phospholipid. Hence, in embodiments wherein the CMC of the two components is different from each other, for example if the long-chain phospholipid is DOPC and the short-chain phospholipid is DHPC.sub.6, the critical micelle concentration of the two compounds is different and the optimal lipid concentration may be adjusted to effect bicellar formation at very low concentrations, depending on the individual CMC values.
(27) The term support as used herein refers to any material which does not react with any of the phospholipids or the produced phospholipid bilayer. The support may include metals, transition metals or metalloids, either in their elemental form or as their oxides or nitrides. Hence, the support may include or may be selected from the group consisting of silicon oxide, gold, aluminum oxide, titanium oxide and silicon nitride. The surface of the support may be a substantially planar surface or the support may be in the form of nanoparticles or colloids. By using a support, a solid-supported phospholipid bilayer (SLB) may be obtained.
(28) The long-chain phospholipid and the short-chain phospholipid in solution may form a bicellar mixture. This bicellar mixture may comprise bicelles, which may be in the form of disk-like aggregates (as mentioned herein). The circular center of this disk may comprise the long-chain phospholipid while the edges of these discs may be stabilized by the short-chain phospholipids. In addition to the bicelles, the short-chain phospholipid may be present in the form of micelles. It is often observed that a too high concentration of the short-chain phospholipid may cause disruption of the formed SLB. This perturbation of the SLB may be due to the surfactant-like properties of the short-chain phospholipid. The disruption or perturbation of the SLB may also be called membrane-induced destabilization. The term membrane as used herein, may refer to the phospholipid bilayer before solidification (and transition into a solid-supported bilayer). Hence, the membrane is the lipid bilayer in a particular phase state. The term membrane phase state would be used for describing, for example, whether the lipid bilayer is in the fluid- or gel-phase state.
(29) While a too high concentration of the short-chain phospholipid may be harmful to the membrane, as discussed above, on the other hand, a too low concentration of the short-chain phospholipid may not facilitate efficient SLB formation, or it would lead to very long reaction times, as the adsorption process on the substrate may be too slow. For this reason, the lowest limit of the concentration of the short-chain phospholipid may be about 0.0001 mM, which would roughly be equivalent to the time scale of a few hours for bilayer fabrication.
(30) Advantageously, it has been found that the method as described above yields optimal phospholipid bilayers when the concentration of the phospholipids is relatively low. Hence, the concentration of the long-chain phospholipid in the solution obtained after the second step and which is to be deposited in the third step is at most 0.1 mg/mL. The concentration of the long-chain phospholipid in the solution of the first step may be higher and may be diluted after the blending of the second step in order to be as low as at most 0.1 mg/mL. The concentration of the long-chain phospholipid is in relation with the short-chain phospholipid, which is, in turn, very low as well. Hence, at this low concentration range, the free concentration of the short-chain phospholipid is sufficiently low to prevent membrane-induced destabilization, resulting in high-quality SLBs via bicelle adsorption and spontaneous rupture after reaching a critical surface coverage. At the same time, the presence of the short-chain phospholipid is important for membrane softening and the disk-like bicellar aggregates exhibit greater deformation in the adsorbed state than conventional vesicles.
(31) In various embodiments, the long-chain phospholipid is a phospholipid comprising two fatty acid residues, wherein each of the fatty acid residues has more than 10 carbon atoms, preferably more than 12 carbon atoms, more preferably more than 16 carbon atoms. Hence, in these embodiments, R.sub.1 and R.sub.2 in Formula (I) above may each individually have an alkyl chain wherein the number of carbon atoms is more than 10 carbon atoms, preferably more than 12 carbon atoms, more preferably more than 16 carbon atoms. The number of carbon atoms may also be in the range of 12 to 24 carbon atoms, or 14 to 22 carbon atoms, or 16 to 20 carbon atoms, or 14 to 18 carbon atoms, preferably 16 to 18 carbon atoms.
(32) In various embodiments, the long-chain phospholipid and/or the short-chain phospholipid may be a phosphatidylcholine. A phosphatidylcholine refers to a phospholipid wherein the hydrophilic portion (R.sub.3 in Formula (I)) comprises a choline moiety. The structure of a phosphatidylcholine may then be represented by the structure of Formula (II) below:
(33) ##STR00002## wherein R.sub.1 and R.sub.2 are as discussed above.
(34) In various embodiments, the long-chain phospholipid has a gel-to-fluid-phase transition temperature of below 0 C., preferably of below 10 C. The gel-to-fluid-phase transition temperature (T.sub.m) as used herein may refer to the temperature required to induce a change in the lipid physical state from the ordered gel phase, where the hydrocarbon chains are fully extended and closely packed, to the disordered liquid phase, where the hydrocarbon chains are randomly oriented and fluid. Advantageously, by having a gel-to-fluid-phase transition temperature of below 0 C., this may ensure fluid-phase membrane states at room temperature and this stable existence in the fluid-phase is important because fluid-phase membranes permit dynamic structural rearrangements and SLB formation can become inhibited at or near the T.sub.m of a phospholipid. Furthermore, when bicellar mixtures are considerably above their transition temperature, they may form fluid-phase membranes in which some short-chain phospholipids are in fast exchange with long-chain phospholipids, and this exchange may cause membrane softening that decreases the bending moduli of membranes.
(35) In various embodiments, the short-chain phospholipid may be a phospholipid comprising two fatty acid residues R.sub.1 and R.sub.2, as shown in Formula (I) above. Hence, they may each have an alkyl chain wherein the number of carbon atoms is at most 10 carbon atoms, preferably at most 8 carbon atoms. The number of carbon atoms may also be in the range of 2 to 10 carbon atoms, or 4 to 10 carbon atoms, or 4 to 8 carbon atoms, preferably 4 to 6 carbon atoms. In one example, the short-chain phospholipid is DHPC.sub.6.
(36) In various embodiments, at least one of the long-chain phospholipid and the short-chain phospholipid may comprise an unsaturated fatty acid residue. Hence, the alkyl chain depicted as R.sub.1 and R.sub.2 may comprise at least one double bond. Advantageously, by comprising an unsaturated fatty acid residue as opposed to a saturated fatty acid residue, the gel-to-fluid-phase transition temperature may be lowered, therefore resulting in the advantages as explained above.
(37) In various embodiments, the long-chain phospholipid may comprise an unsaturated fatty acid residue. In one example, the long-chain phospholipid is DOPC.
(38) In one specific example, the long-chain phospholipid is DOPC and the short-chain phospholipid is DHPC.sub.6.
(39) In various embodiments, the concentration of the long-chain phospholipid is at most 0.05 mg/mL, preferably at most 0.025 mg/mL. As mentioned above, one of the advantages of the presently disclosed method is using a relatively low concentration of phospholipids in the solution in the third step. The low concentration of the long-chain phospholipid is in relation with a low concentration of the short-chain phospholipid.
(40) Hence, in various embodiments, the long-chain phospholipid and the short-chain phospholipid are provided in a molar ratio of about 1:0.02 to about 1:5, preferably in a ratio of about 1:0.04 to about 1:3. In specific embodiments, the ratio may be about 1:0.2 to about 1:2.6.
(41) A ratio as described above may result, according to various embodiments referring to the first step, in the solution comprising a bicellar mixture, as described above, wherein the bicellar mixture comprises bicelles of the long-chain phospholipid and the short-chain phospholipid.
(42) The formation of bicellar mixtures may be dependent on the environment. Hence, in various embodiments, the solvent utilized to make the solution may be a water-based buffer solution, preferably a water-based buffer solution with an effective pH range of between 7 and 10, more preferably between 7.5 and 9.0. In one example, the water-based buffer solution is an aqueous solution comprising Tris (tris(hydroxymethyl)aminomethane) and sodium chloride and the pH value of this buffer solution may be about 7.5.
(43) As mentioned above, the support may comprise or consist of an inorganic material. The inorganic material may be selected from various inorganic materials comprising metals, transition metals, and metalloids. The term transition metal is to be interpreted broadly to include any element in which the filling of the outermost shell to eight electrons within a periodic table is interrupted to bring the penultimate shell from 8 to 18 or 32 electrons. Transition elements may include, without limitation, scandium, titanium, vanadium, chromium, manganese, iron, cobalt, nickel, copper, zinc, ytterbium, zirconium, niobium, molybdenum, silver, lanthanum, hafnium, tantalum, tungsten, rhenium, rare-earth elements, cerium, praseodymium, neodymium, promethium, samarium, europium, gadolinium, terbium, dysprosium, holmium, erbium, thulium, yttrium, lutetium, and rhodium. Included in this definition are post-transition metals, which may refer to the metallic elements in the periodic table located between the transition metals (to their left) and the metalloids (to their right). These elements may include gallium, indium, thallium, tin, lead, bismuth, cadmium, mercury and aluminum. The metalloids may include boron, silicon, germanium, arsenic, antimony, tellurium, polonium and astatine. The metals, transition metals and metalloids may either be elemental or in form of their salts, for example, as the oxide, nitride, sulfate and phosphate.
(44) In various embodiments, the surface of the support may be substantially planar. The term substantially planar may refer to the surface representing one plane, which is substantially linear. The SLB may then be immobilized on an inorganic solid support.
(45) In alternative embodiments, the surface of the support may be nanostructured. In specific embodiments, the nanostructured surface may be in the form of colloids or nanoparticles. The SLB would then provide a coating on the inorganic colloids or nanoparticles. Advantageously, by coating an SLB on nanoparticles, for example on oxide or nitride inorganic support materials, the SLB may be further functionalized to be used in electronic and biomedical applications.
(46) In the freeze-thaw-vortex process in the second step, the temperature of the solution may be decreased. In various embodiments, the temperature of the solution may be decreased, optionally from room temperature, to below 0 C., or to below 5 C., or to below 10 C., or to below 50 C., preferably to below 100 C., more preferably to below 150 C. In one example, the temperature of the solution may be decreased to the temperature of liquid nitrogen (195.79 C.). The term room temperature as used herein, also called ambient temperature, refers to a temperature which may be between 15 C. and 25 C., or between 18 C. and 22 C.
(47) In the freeze-thaw-vortex process in the second step, and after the cooling step described before, the temperature of the solution may be increased. In various embodiments, the temperature of the solution may be increased to above room temperature, or to above 30 C., or to above 40 C., more preferably to above 50 C. In one example, the temperature of the solution may be increased to 60 C.
(48) As mentioned before, the solution may be blended in the second step. While any blending method may be used, in preferred embodiments, the blending may be undertaken by vortexing the solution. In various embodiments, the freeze-thaw-vortex process, as described above as the second step, may be repeated. Hence, the second step may be repeated for about at least 2, or 3, preferably for about 4 times or more.
(49) After the freeze-thaw-vortex process, as described above as, the second step may optionally comprise a dilution step. In this step, the solution obtained after the blending of the freeze-thaw-vortex process carried out in the second step may be diluted in order to obtain the concentration of the long-chain phospholipid in the solution being at most 0.1 mg/mL. In the event the freeze-thaw-vortex process is repeated, the dilution would only be carried out after the last blending step of the freeze-thaw-vortex process.
(50) The process comprises a third step. In the third step, the solution obtained after the second step is deposited on a surface of a support, wherein the concentration of the long-chain phospholipid in the solution is at most 0.1 mg/mL, for obtaining a solid-supported phospholipid bilayer. According to various embodiments, in the third step of the method, the bicellar mixture may rupture in order to obtain the solid-supported phospholipid bilayer. The rupturing may be a result of reaching a critical bicelle concentration followed by adsorption on the substrate.
(51) In various embodiments, the third step may be followed by a washing step. The washing step may comprise washing the obtained solid-supported phospholipid bilayer with a buffer solution.
(52) Advantageously, the method as presented herein does not require the use of a surfactant.
(53) Further advantageously, the method as presented herein does not require the use of vesicles. Advantageously, this may avoid extensive sample preparation.
(54) Further advantageously, the obtained solid-supported phospholipid bilayer may be a planar phospholipid layer on the support.
(55) In a second aspect, a solid-supported phospholipid bilayer is provided. The solid-supported phospholipid bilayer may be obtained by the method as described above.
(56) Advantageously, the phospholipid bilayer may cover more than 90% of the surface of the support. The obtained phospholipid bilayer may have a thickness of about 2 to about 7 nanometers. In preferred embodiments, the obtained phospholipid bilayer may have a thickness of about 3 to about 6 nanometers.
(57) In some embodiments, the obtained phospholipid bilayer may comprise or consist of an SLB of DHPC.sub.6 and DOPC. In alternative embodiments, the obtained phospholipid bilayer may comprise or consist of an SLB of substantially only DOPC. Substantially, as used herein, may refer to a content of more than 90%, or more than 95%.
(58) An important consideration in the present disclosure involves selecting the range of total lipid concentration. It was explored whether successful SLB formation is possible at lower phospholipid concentrations than reported in previous bicellar studies. In particular, by lowering the total phospholipid concentration, phospholipid aggregates in bulk solution as well as those adsorbed onto the surface would be mainly composed of DOPC phospholipids since DHPC.sub.6 phospholipids would be preferentially in the monomeric state. Hence, it is necessary to find the optimal range whereby the bicellar mixture facilitates efficient SLB formation (i.e., DHPC.sub.6 concentration is sufficiently high to promote SLB formation) while minimizing deleterious effects of short-chain phospholipid detergents (i.e., keeping the DHPC.sub.6 concentration below a critical concentration that causes membrane destabilization). Of note, since DOPC and DHPC.sub.6 are in a mixed micelle system, the critical micelle concentration (CMC) of DHPC.sub.6 is affected by the presence of DOPC and hence CMC values of DHPC.sub.6 alone are insufficient to describe the system under investigation, especially with varying q-ratios, in the context of preventing surfactant-induced perturbations in SLB structure Important aspects of the present disclosure include the combination of the following: The presented method can form high-quality supported lipid bilayers in fully aqueous conditions. The presented method can form high-quality supported lipid bilayers with minimal sample preparation (no vesicles). The presented method can form high-quality supported lipid bilayers at very low lipid concentrations (4-10 times lower than other methods).
(59) The inventors have identified optimal conditions for preparing SLBs by utilizing bicellar mixtures. While previous bicelle-related studies have used high phospholipid concentrations (between 0.25 and 0.8 mg/mL long-chain phospholipid) to prepare SLBs, the present findings reveal that SLB quality is optimal when using bicellar mixtures at appreciably lower concentrations of 0.024 mg/mL of the long-chain phospholipid or lower. In this concentration range, the free DHPC.sub.6 concentration is sufficiently low to prevent membrane-induced destabilization, resulting in high-quality SLBs via bicelle adsorption and spontaneous rupture after reaching a critical surface coverage. At the same time, the presence of DHPC.sub.6 in the bicellar mixture is important for membrane softening and the disk-like bicellar aggregates exhibit greater deformation in the adsorbed state than conventional vesicles. Furthermore, compared to vesicle preparation methods, bicelle preparation is simple and only requires freeze-thaw-vortex cycling, and the concentration range used to form high-quality SLBs is approximately 5 to 10-times lower than the minimum lipid concentration required for the SALB method (0.1 mg/mL). The advantages over existing methods are illustrated in the below Table 1:
(60) TABLE-US-00001 TABLE 1 Specialized Phospholipid Method Preparation Concentration Bilayer Quality Vesicle Yes ~0.1 mg/mL or higher 2 Fusion SALB No 0.1-0.5 mg/mL 3 Conventional No 0.25 mg/mL or higher 4 Bicelle Invention No 0.08 mg/mL or lower 1 Ranking: 1 is best combination of completeness, free of defects, and reproducibility. 4 is worst.
(61) Hereinafter, the present disclosure will be described more fully with reference to the accompanying drawings, in which exemplary embodiments of the invention are shown. This invention may, however, be embodied in many different forms and should not be construed as limited to the exemplary embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. In the drawings, lengths and sizes of layers and regions may be exaggerated for clarity.
EXPERIMENTAL SECTION
(62) Materials and Methods
Example 1: Preparation of DOPC/DHPC.SUB.6 .Bicellar Mixtures
(63) 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dihexyanoyl-sn-glycero-3-phosphocholine (DHPC) were purchased from Avanti Polar Lipids (Alabaster, Ala.). In the context of the description, whenever DHPC in this Examples section is stated, it refers to DHPC.sub.6 (1,2-dihexyanoyl-sn-glycero-3-phosphocholine). DOPC dissolved in chloroform was dried with a gentle stream of nitrogen and evaporated in a vacuum desiccator overnight. The DOPC film was hydrated with a buffer solution (10 mM Tris, 150 mM NaCl, pH 7.5) that contained the appropriate DHPC concentration to make 1 mL of 1 mM DOPC stock solutions for different q-ratios (as defined by [DOPC]/[DHPC]). Subsequently, the sample was plunged into liquid nitrogen for 1 minute, followed by a 5-minute incubation period in a 60 C. water bath and vortexing for 30 seconds. This freeze-thaw-vortex cycle was repeated 5 times unless otherwise noted. The final bicellar mixture was optically clear at room temperature. Before experiment, the stock solution was diluted in buffer (10 mM Tris, 150 mM NaCl, pH 7.5) to the desired final lipid concentration.
Example 2: Quartz Crystal Microbalance-Dissipation (QCM-D) Experiments
(64) QCM-D experiments were conducted with a Q-Sense E4 instrument (Biolin Scientific AB, Stockholm, Sweden) in order to monitor the SLB formation process. The QCM-D is a label-free measurement technique that is sensitive to the mass and viscoelastic properties of an adsorbate on the surface by measuring changes in the resonance frequency and energy dissipation of an oscillating, piezoelectric quartz crystal sensor chip. The sensor chip had a fundamental frequency of 5 MHz and a sputter-coated, 50-nm-thick layer of silicon dioxide (model no. QSX 303, Biolin Scientific AB). Before the experiment, the sensor chips were thoroughly rinsed with ethanol, dried with nitrogen gas, and treated with oxygen plasma for 1 minute. In the experiment, a baseline signal with aqueous buffer solution (10 mM Tris, 150 mM NaCl, pH 7.5) was established shortly before injection of the bicellar mixture under continuous flow conditions. Following SLB formation, 50 M of bovine serum albumin was added under continuous flow conditions for 10 minutes in order to quantify the degree of bilayer completeness. Throughout the experiment, liquid samples were injected at 50 L/minute by using a peristaltic pump (Reglo Digital, Ismatec, Glattbrugg, Switzerland). The temperature was maintained at 25.00.5 C. The experiments were recorded at odd-numbered overtones ranging from the 3.sup.rd to 11th odd overtone by using the Q-Soft software package (Biolin Scientific AB), with the presented data recorded at the 5.sup.th odd overtone. Data processing and analysis were completed using the QTools (Biolin Scientific AB) and OriginPro 8.5 (OriginLab, Northampton, Mass.) software packages.
Example 3: Fluorescence Microscopy Experiments
(65) Epifluorescence microscopy was performed to directly observe the SLB formation process. For these experiments, the long-chain phospholipid composition included a mixture of 99.5 mol % DOPC and fluorescently labeled 0.5 mol % 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) lipid. An Eclipse TI-U inverted optical microscope (Nikon, Japan) with a 60 magnification (NA=1.49) oil-immersion objective lens (Nikon) was used, and images were recorded with an iXon 512 pixel512 pixel EMCCD camera (Andor Technology, Northern Ireland). The pixel size was 0.2670.267 m.sup.2. A fiber-coupled mercury lamp (Intensilight C-HGFIE, Nikon) was used to illuminate the fluorophores with a TRITC filter. SLBs were formed inside a microfluidic flow-through chamber (sticky slide VI 0.4, Ibidi, Germany) through the injection of a bicellar mixture under continuous flow conditions at 40 L/minute. After formation, the lipid bilayer was rinsed with buffer solution (10 mM Tris, 150 mM NaCl, pH 7.5). The process of SLB formation, followed by buffer rinsing, was captured through time-lapsed image recording every 5 seconds. The initial time, t=0 s, was defined by when the bicellar mixture reached the channel inlets. For each measurement recorded, the fluorescence intensity of each image was normalized using a custom-written script for the Python(x,y) 2.7.5 software program.
Example 4: Fluorescence Recovery after Photobleaching (FRAP)
(66) FRAP measurements were conducted by a 5-second photobleaching of a circular spot of 20 m diameter within fabricated SLBs by using a 532 nm, 100 mW laser (Klastech Laser Technologies, Dortmund). Subsequently, fluorescence micrographs were imaged for 120 s at 1 s intervals in order to calculate lateral diffusion coefficients using the Hankel transform method.
(67) Results and Discussion
Example 5: Design Rationale
(68) In general, bicellar mixtures are composed of a mixture of vesicles containing both long-chain and short-chain phospholipids, which are in dynamic equilibrium with micelles composed of the short-chain phospholipid. Past studies about utilizing bicellar mixtures to form SLBs have used either DMPC or DPPC as the long-chain phospholipid in the bicellar composition. Herein, it was decided to use the DOPC lipid instead and it is also capable of forming bicelles, as previously reported. While DMPC and DPPC have gel-to-fluid phase transition temperatures (T.sub.m) of 23 and 41 C., respectively, DOPC has a lower T.sub.m of 20 C., which ensures fluid-phase membrane states at room temperature and this stable existence in the fluid-phase is important because fluid-phase membranes permit dynamic structural rearrangements and SLB formation can become inhibited at or near the T.sub.m of a phospholipid. Furthermore, when bicellar mixtures are considerably above their transition temperature, they form fluid-phase membranes in which some DHPC molecules are in fast exchange with long-chain phospholipids, and this exchange causes membrane softening that decreases the bending moduli of membranes.
Example 6: QCM-D Monitoring of Bicelle Adsorption onto Silicon Dioxide
(69) To investigate SLB formation through the adsorption of bicellar mixtures composed of DOPC and DHPC phospholipids, the QCM-D technique was employed in order to monitor the bilayer formation process on silicon dioxide. The QCM-D technique is a label-free acoustic sensor that measures the mass and viscoelastic properties of a thin film adsorbed based on recording changes in resonance frequency and energy dissipation, respectively. It is commonly used for lipid adsorption studies, especially those involving vesicle adsorption and rupture leading to SLB formation, and can distinguish between different morphological states of adsorbed phospholipid molecules. The effects of total DOPC/DHPC lipid concentration on bicelle adsorption and SLB formation were tested at three different q-ratios: 0.05, 0.25, and 2.5, as described below.
Example 7: q-Ratio of 0.05
(70)
(71) By contrast, at lower lipid concentrations (0.063 mM DOPC and below), similar adsorption behavior was observed and there was a larger f shift at the critical coverage (inflection point) (ca. 50 Hz) and D shifts around 2.510.sup.6 (
(72) For SLBs prepared under all tested conditions, 50 M bovine serum albumin (BSA) was added after the buffer rinsing step in order to estimate the degree of SLB completeness across the sensor surface. While BSA adsorbs prodigiously onto silicon dioxide, there is known to be scant adsorption onto zwitterionic SLBs, and the difference in f shifts can be used to estimate the percentage of completeness. Whereas BSA adsorption onto bare silicon dioxide substrate yielded f shifts around 25 Hz, BSA adsorption onto SLB-coated silicon dioxide caused much smaller f shifts of 1.60.2 Hz, indicating high (94%) surface coverage of the SLBs on silicon dioxide.
Example 8: q-Ratio of 0.25
(73)
(74) By contrast, at lower DOPC concentrations of 0.063 mM and lower, the effect of residual DHPC on SLB quality was negligible and the f and D shifts were 24.80.7 Hz and 010.sup.6, respectively (
Example 9: q Value of 2.5
(75)
(76) On the other hand, at lower DOPC concentrations of 0.063 mM and below, the final f and D values were 25.70.9 Hz and 0.010.sup.6, respectively (
(77) To better understand the effect of DHPC on destabilizing fabricated SLBs, control experiments were conducted investigating the effect of adding DHPC molecules at various concentrations to preformed DOPCs prepared by the SALB method (
Example 10: Evidence of a Critical Bicelle Concentration
(78) The aforementioned QCM-D experiments support that a critical coverage of adsorbed bicelles is necessary to induce SLB formation and that the process likely occurs via a membrane rupture mechanism that bears similarities to conventional vesicle adsorption and spontaneous rupture. To confirm that a critical coverage of adsorbed bicelles is necessary for SLB formation, we performed a stop-flow experiment in which bicelles were injected until reaching a surface coverage below the critical coverage and then the bicelle solution was exchanged with buffer solution (without bicelles). For this experiment, the bicelles had a q-ratio of 2.5 and a DOPC concentration of 0.031 mM. As presented in
(79) Next, time-independent plots of energy dissipation shifts were constructed as a function of frequency shifts based on the QCM-D measurements tracking the SLB formation process from adsorbed bicelles at the various tested q-ratios (0.05, 0.25, 2.5:0.063 mM DOPC lipid concentration) as well as 0.063 mM DOPC lipid vesicles that were similarly processed with freeze-thaw treatment (
Example 11: Direct Observation of Supported Lipid Bilayer Formation from Bicellar Mixtures
(80) In order to directly observe bicelle adsorption and rupture leading to SLB formation, time-lapsed fluorescence microscopy experiments were performed under continuous flow conditions on glass substrates using bicelles prepared at the different q-ratios. Specifically, the objective was to capture the bicelle rupture process when the critical bicelle concentration (CBC) is reached and the first micrograph in each series presented below corresponds to the time when fusion/rupture processes and ensuing SLB formation begin. On the basis of the previous QCM-D measurements, a specific DOPC concentration of 0.031 mM was chosen for further investigation based on the optimal conditions which yielded high-quality SLBs. The experimental results obtained for each q-ratio are described below and t=0 minutes is defined as the time point when bicelles first reached the measurement chamber.
Example 12: q-Ratio of 0.05
(81) As shown in
Example 13: q-Ratio of 0.25
(82) A similar process of bicelle rupture and SLB propagation was observed using bicelles at a q-ratio of 0.25 as well (
Example 14: q-Ratio of 2.5
(83) SLB formation using bicelles at a q-ratio of 2.5 followed a similar trend to the cases described above (
(84) In summary, the fluorescence microscopy experiments strongly support the QCM-D experiments by identifying that SLB formation occurs upon reaching a critical number of adsorbed bicelles, which induces bicelle rupture. While the kinetic stages of the process are similar to vesicle adsorption and spontaneous rupture after reaching a critical coverage, it is important to recall that DHPC causes membrane softening and also likely further aids SLB formation by activating the edges of the bilayer patches upon contact with adsorbing bicelles. In this case, DHPC would function as edge-activators, as seen in so-called elastic vesicles, and aid bilayer propagation until the SLB formation process is complete.
Example 15: FRAP Characterization
(85) The lateral lipid diffusion of the fabricated SLBs was also characterized by FRAP measurements for the bicelles prepared at the various q-ratios (with fixed DOPC concentration at 0.031 mM). Time-lapsed FRAP micrographs indicated that nearly complete fluorescence recovery is observed within 2 minutes (
Example 16: Influence of Bicelle Preparation Conditions
(86) Lastly, it was investigated how the preparation of DOPC/DHPC bicellar mixtures (q-ratio of 0.25; 0.063 mM DOPC) influences SLB formation on silicon dioxide, as determined by QCM-D measurements (
(87) While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it will be understood by those of ordinary skill in the art that various changes in form and details may be made therein without departing from the spirit and scope of the present invention as defined by the following claims.